Cholestin public comments to be accepted by FDA until Jan. 30.
This article was originally published in The Tan Sheet
Executive Summary
CHOLESTIN PUBLIC COMMENTS TO BE ACCEPTED BY FDA UNTIL JAN. 30, according to an agency notice in the Jan. 13 Federal Register. The notice invites comments on the regulatory status of the product, marketed by Pharmanex as a dietary supplement for cholesterol reduction, and provides additional time for submissions. The agency disclosed it was initiating an administrative proceeding on the issue in a Nov. 14 letter to Pharmanex and said it would target the end of 1997 for a final decision ("The Tan Sheet" Dec. 1, 1997, p. 6). The letter responded to a citizen petition from Pharmanex requesting a stay of enforcement action against Cholestin.